NervGen Pharma Statistics
Total Valuation
NervGen Pharma has a market cap or net worth of $321.89 million. The enterprise value is $309.25 million.
Important Dates
The last earnings date was Thursday, April 2, 2026.
| Earnings Date | Apr 2, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NervGen Pharma has 80.93 million shares outstanding. The number of shares has increased by 7.44% in one year.
| Current Share Class | 80.93M |
| Shares Outstanding | 80.93M |
| Shares Change (YoY) | +7.44% |
| Shares Change (QoQ) | +0.47% |
| Owned by Insiders (%) | 2.49% |
| Owned by Institutions (%) | 3.55% |
| Float | 68.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 121.87 |
| P/TBV Ratio | 145.41 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.16, with a Debt / Equity ratio of 0.00.
| Current Ratio | 1.16 |
| Quick Ratio | 1.12 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -1,457.57% and return on invested capital (ROIC) is -508.29%.
| Return on Equity (ROE) | -1,457.57% |
| Return on Assets (ROA) | -73.42% |
| Return on Invested Capital (ROIC) | -508.29% |
| Return on Capital Employed (ROCE) | -721.31% |
| Weighted Average Cost of Capital (WACC) | 9.69% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.60M |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +87.79% in the last 52 weeks. The beta is 0.99, so NervGen Pharma's price volatility has been similar to the market average.
| Beta (5Y) | 0.99 |
| 52-Week Price Change | +87.79% |
| 50-Day Moving Average | 4.05 |
| 200-Day Moving Average | 3.52 |
| Relative Strength Index (RSI) | 48.14 |
| Average Volume (20 Days) | 229,719 |
Short Selling Information
The latest short interest is 1.35 million, so 1.67% of the outstanding shares have been sold short.
| Short Interest | 1.35M |
| Short Previous Month | n/a |
| Short % of Shares Out | 1.67% |
| Short % of Float | 1.96% |
| Short Ratio (days to cover) | 11.92 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -18.29M |
| Pretax Income | -32.18M |
| Net Income | -32.18M |
| EBITDA | -18.25M |
| EBIT | -18.29M |
| Earnings Per Share (EPS) | -$0.44 |
Full Income StatementBalance Sheet
The company has $16.10 million in cash and $6,104 in debt, with a net cash position of $16.09 million or $0.20 per share.
| Cash & Cash Equivalents | 16.10M |
| Total Debt | 6,104 |
| Net Cash | 16.09M |
| Net Cash Per Share | $0.20 |
| Equity (Book Value) | 2.54M |
| Book Value Per Share | 0.03 |
| Working Capital | 2.24M |
Full Balance SheetCash Flow
| Operating Cash Flow | -14.22M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 40,874 |
| Net Borrowing | -73,935 |
| Free Cash Flow | -14.28M |
| FCF Per Share | -$0.18 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
